AC Immune

AC Immune reported 74.8 million Swiss francs in cash and short‑term financial assets at March 31, 2026 and indicates runway into the fourth quarter of 2027, aided by partnerships. The company reported 69.3 million Swiss francs of operating cash outflow in 2025, reflecting the capital intensity of clinical development.

There is no financial debt disclosed, but sustainability depends on milestone timing and/or future capital raises. Overall liquidity is adequate for near‑term catalysts, but not yet self‑funding.